Informed Consent for INVOcell
Feb, 9 2016

In Vitro Fertilization via INVOcell
Process, Risk, and Consent

In Vitro Fertilization (IVF) has become an established treatment for many forms of infertility. The main goal of IVF is to allow a patient the opportunity to become pregnant using her own eggs or donor eggs and sperm from her partner or from a donor. This is an elective procedure designed to result in the patient’s pregnancy when other treatments have failed or are not appropriate.

This consent reviews the IVF process from start to finish, including the risks that this treatment might pose to you and your offspring. While best efforts have been made to disclose all known risks, there may be risks of IVF that are not yet clarified or even suspected at the time of this writing.

An IVF cycle typically includes the following steps or procedures:
- Medications to grow multiple eggs
- Retrieval of eggs from the ovary or ovaries
- Insemination of eggs with sperm
- Culture of any resulting fertilized eggs (embryos)
- Placement (“transfer”) of one or more embryo(s) into the uterus
- Support of the uterine lining with hormones to permit and sustain pregnancy

In certain cases, these additional procedures can be employed:
- Cryopreservation (freezing) of embryos

Note: At various points in this document, rates are given which reflect what are believed to be U.S. national averages for those employing IVF treatments. These include items such as pregnancy rates, Cesarean delivery rates, and preterm delivery rates. These rates are not meant to indicate the rates of these outcomes within individual practices offering IVF, and are not to be understood as such. Individual practices may have higher or lower pregnancy and delivery rates than these national averages, and also higher or lower risks for certain complications. It is appropriate to ask the practice about their specific rates.

Also note that while this information is believed to be up to date at the time of publication (2013), newer reports may not yet be incorporated into this document.
IVF Procedures

Medications for IVF Treatment

- The success of IVF largely depends on growing multiple eggs at once.
- Injections of the natural hormones FSH and/or LH (gonadotropins) are used for this purpose.
- Additional medications are used to prevent premature ovulation.
- An overly vigorous ovarian response can occur, or conversely an inadequate response.

Medications may include the following (not a complete list):

- **Gonadotropins, or injectable “fertility drugs”** (Follistim®, Gonal-F®, Bravelle®, Menopur®): These natural hormones stimulate the ovary in hopes of inducing the simultaneous growth of several oocytes (eggs) over the span of 8 or more days. All injectable fertility drugs have FSH (follicle stimulating hormone), a hormone that will stimulate the growth of your ovarian follicles (which contain the eggs). Some of them also contain LH (luteinizing hormone) or LH-like activity. LH is a hormone that may work with FSH to increase the production of estrogen and growth of the follicles. Low-dose hCG (human chorionic gonadotropin) can be used in lieu of LH. These medications are given by subcutaneous or intramuscular injection. Proper dosage of these drugs and the timing of egg recovery require monitoring of the ovarian response, usually by way of blood tests and ultrasound examinations during the ovarian stimulation.

As with all injectable medications, bruising, redness, swelling, or discomfort can occur at the injection site. Rarely, there can be an allergic reaction to these drugs. The intent of giving these medications is to mature multiple follicles, and many women experience some bloating and mild discomfort as the follicles grow and the ovaries become temporarily enlarged. Up to 2.0 % of women will develop Ovarian Hyperstimulation Syndrome (OHSS) [see full discussion of OHSS in the Risks to Women section that follows]. Other risks and side effects of gonadotropins include, but are not limited to, fatigue, headaches, weight gain, mood swings, nausea, and clots in blood vessels.

Even with pre-treatment attempts to assess response, and even more so with abnormal pre-treatment evaluations of ovarian reserve, the stimulation may result in very few follicles developing. The end result may be few or no eggs obtained at egg retrieval or even cancellation of the treatment cycle prior to egg retrieval.

Concerns have been raised that the risk of ovarian cancer may increase with the use of fertility drugs, but recent studies have not confirmed this. A major risk factor for ovarian cancer is infertility per se, and early reports may have falsely attributed the risk resulting from infertility to the use of medications to overcome it (see 2.b.2 for further discussion).

- **GnRH-agonists (leuprolide acetate) (Lupron®)**: This medication is taken by injection. There are two forms of the medication: A short acting medication requiring daily injections and a long-acting preparation lasting for 1-3 months. The primary role of this medication is to prevent a premature LH surge, which could result in the release of eggs before they are ready to be retrieved. Since GnRH-agonists initially cause a release of FSH and LH from the pituitary, they can also be used to start the growth of the follicles or initiate the final stages of egg maturation. Though leuprolide acetate is an FDA (U.S. Food and Drug Administration) approved medication, it has not been approved for use in IVF, although it has routinely been used in this way for more than 20 years. Potential side effects usually experienced with long-term use include, but are not limited to: hot flashes, vaginal dryness, bone loss, nausea, vomiting, skin reactions at the injection site, fluid retention, muscle aches, headaches, and depression. No long term or serious side effects are known. Since GnRH-a are oftentimes administered after
ovulation, it is possible that they will be taken early in pregnancy. The safest course of action is to use a barrier method of contraception (condoms) the month you will be starting the GnRH-a. GnRH-a has not been associated with any fetal malformations, however you should discontinue use of the GnRH-a immediately if pregnancy is confirmed.

- **Human chorionic gonadotropin (hCG)** (Profasi®, Novarel®, Pregnyl®, Ovidrel®): hCG is a natural hormone used in IVF to induce the eggs to become mature and fertilizable. The timing of this medication is critical to retrieve mature eggs. Potential side effects include, but are not limited to: breast tenderness, bloating, and pelvic discomfort.

- **Progesterone, and in some cases, estradiol**: Progesterone and estradiol are hormones normally produced by the ovaries after ovulation. After egg retrieval in some women, the ovaries will not produce adequate amounts of these hormones for long enough to fully support a pregnancy. Accordingly, supplemental progesterone, and in some cases estradiol, are given to ensure adequate hormonal support of the uterine lining. Progesterone is usually given by injection or by the vaginal route (Endometrin®, Crinone®, Prochieve®, Prometrium®, or pharmacist-compounded suppositories) after egg retrieval. Progesterone is often continued for some weeks after a pregnancy has been confirmed. Progesterone has not been associated with an increase in fetal abnormalities. Side effects of progesterone include depression, sleepiness, allergic reaction, and if given by intra-muscular injection, includes the additional risk of infection or pain at the injection site. Estradiol, if given, can be by oral, trans-dermal, intramuscular, or vaginal administration. Side effects of estradiol include nausea, irritation at the application site if given by the trans-dermal route and the risk of blood clots or stroke.

- **Oral contraceptive pills**: Some treatment protocols include oral contraceptive pills to be taken for 2 to 4 weeks before gonadotropin injections are started in order to suppress hormone production or to schedule a cycle. Side effects include unscheduled bleeding, headache, breast tenderness, nausea, swelling and the risk of blood clots or, very rarely, stroke.

- **Other medications**: Antibiotics may be given for a short time during the treatment cycle to reduce the risk of infection associated with egg retrieval or embryo transfer. Antibiotic use may be associated with vaginal yeast infection, nausea, vomiting, diarrhea, rashes, sensitivity to the sun, and allergic reactions. Anti-anxiety medications or muscle relaxants may be recommended prior to the embryo transfer. The most common side effect is drowsiness. Other medications such as steroids, heparin, low molecular weight heparin or aspirin may also be included in the treatment protocol.

**Transvaginal Oocyte (Egg) Retrieval**

- Eggs are removed from the ovary with a needle under ultrasound guidance.
- Anesthesia is provided to make this comfortable.
- Complications are rare.
Oocyte retrieval is the removal of eggs from the ovary. A transvaginal ultrasound probe is used to visualize the ovaries and the egg-containing follicles within the ovaries. A long needle, which can be seen on ultrasound, can be guided into each follicle and the contents aspirated. The aspirated material includes follicular fluid, oocytes (eggs) and granulosa (egg-supporting) cells. Rarely, the ovaries are not accessible by the transvaginal route and laparoscopy or trans-abdominal retrieval is necessary. These procedures and risks will be discussed with you by your doctor if applicable. Anesthesia is generally used to reduce, if not eliminate, discomfort. Risks of egg retrieval include:

**Infection**: Bacteria normally present in the vagina may be inadvertently transferred into the abdominal cavity by the needle. These bacteria may cause an infection of the uterus, fallopian tubes, ovaries or other intra-abdominal organs. The estimated incidence of infection after egg retrieval is less than 0.1%. Treatment of infections could require the use of oral or intravenous antibiotics. Severe infections occasionally require surgery to remove infected tissue. Infections can have a negative impact on future fertility. Prophylactic antibiotics are sometimes used before the egg retrieval procedure to reduce the risk of pelvic or abdominal infection in patients at higher risk of this complication. Despite the use of antibiotics, there is no way to eliminate this risk completely.

**Bleeding**: The needle passes through the vaginal wall and into the ovary to obtain the eggs. Both of these structures contain blood vessels. In addition, there are other blood vessels nearby. Small amounts of blood loss are common during egg retrievals. The incidence of major bleeding problems has been estimated to be less than 0.1%. Major bleeding may require surgical repair and possibly loss of the ovary. The need for blood transfusion is rare. (Although very rare, review of the world experience with IVF indicates that unrecognized bleeding has lead to death.)

**Trauma**: Despite the use of ultrasound guidance, it is possible to damage other intra-abdominal organs during the egg retrieval. Previous reports in the medical literature have noted damage to the bowel, appendix, bladder, ureters, and ovary. Damage to internal organs may result in the need for additional treatment such as surgery for repair or removal of the damaged organ. However, the risk of such trauma is very low.

**Anesthesia**: The use of anesthesia during the egg retrieval can produce unintended complications such as an allergic reaction, low blood pressure, nausea or vomiting and in rare cases, death.

**Failure**: It is possible that the aspiration will fail to obtain any eggs or the eggs may be abnormal or of poor quality and otherwise fail to produce a viable pregnancy.

**In vitro fertilization and embryo culture**

- Sperm and eggs are placed together in specialized conditions (culture media) to achieve fertilization.
- Culture medium is designed to permit normal fertilization and early embryo development.
- Embryo development helps distinguish embryos with more potential from those with less or none.

After eggs are retrieved, they are transferred to the embryology laboratory where they are kept in conditions that support their needs. The inseminated eggs are placed in the INVOcell device containing "culture medium," which is special fluid developed to support development of the eggs and embryos made to resemble that found in the fallopian tube or uterus. After eggs are retrieved, sperm are placed in the culture medium with the eggs. The eggs are then placed in the INVOcell device, where they remain to develop. The INVOcell device is in turn placed into the vagina so that appropriate culture conditions can be achieved (temperature and pH). Five days later, the device will be removed and the culture media containing the eggs / developing embryos will be inspected. By this time, most normally developing embryos have developed to the
The blastocyst stage, which is typified by an embryo that now has 80 or more cells, an inner fluid-filled cavity, and a small cluster of cells called the inner cell mass.

It is important to note that since many eggs and embryos are abnormal, it is expected that not all eggs will fertilize and not all embryos will divide at a normal rate. The chance that a developing embryo will produce a pregnancy is related to many factors including whether its development in the lab is normal, but this correlation is not perfect. This means that not all embryos developing at the normal rate are in fact also genetically normal, and not all poorly developing embryos are genetically abnormal. Nonetheless, their visual appearance is the most common and useful guide in the selection of the best embryo(s) for transfer.

In spite of reasonable precautions, any of the following may occur in the lab that would prevent the establishment of a pregnancy:

- Fertilization of the egg(s) may fail to occur.
- An egg may be fertilized abnormally resulting in an abnormal number of chromosomes in the embryo; these abnormal embryos will not be transferred.
- The fertilized eggs may degenerate before dividing into embryos, or adequate embryonic development may fail to occur.
- Bacterial contamination or a laboratory accident may result in loss or damage to some or all of the eggs or embryos.
- Laboratory equipment may fail, and/or extended power losses can occur which could lead to the destruction of eggs, sperm and embryos.
- Other unforeseen circumstances may prevent any step of the procedure to be performed or prevent the establishment of a pregnancy.
- Hurricanes, floods, or other “acts of God” (including bombnings or other terrorist acts) could destroy the laboratory or its contents, including any sperm, eggs, or embryos being stored there.

Quality control in the lab is extremely important. Sometimes immature or unfertilized eggs, sperm or abnormal embryos (abnormally fertilized eggs or embryos whose lack of development indicates they are not of sufficient quality to be transferred) that would normally be discarded can be used for quality control. This material may be used for quality control purposes before being discarded in accordance with normal laboratory procedures and applicable laws. None of this material will be utilized to establish a pregnancy or a cell line.

**Embryo transfer**

- After a few days of development, the best appearing embryos are selected for transfer.
- The number chosen influences the pregnancy rate and the multiple pregnancy rate.
- A woman’s age and the appearance of the developing embryo have the greatest influences on pregnancy outcome.
- Embryos are placed in the uterine cavity with a thin tube.
- Excess embryos of sufficient quality that are not transferred can be frozen.
After a few days of development, one or more embryos are selected for transfer to the uterine cavity. Embryos are placed in the uterine cavity with a thin tube (catheter). Ultrasound guidance may be used to help guide the catheter or confirm placement through the cervix and into the uterine cavity. Although the possibility of a complication from the embryo transfer is very rare, risks include infection and loss of, or damage to, the embryos.

The number of embryos transferred influences the pregnancy rate and the multiple pregnancy rate. The age of the woman and the appearance of the developing embryo have the greatest influence on pregnancy outcome and the chance for multiple pregnancy. While it is possible, it is unusual to develop more fetuses than the number of embryos transferred. It is critical to discuss with your doctor the number to be transferred before the transfer is done.

In an effort to help curtail the problem of multiple pregnancies (see multiple pregnancies), national guidelines published in 2013 recommend limits on the number of embryos to transfer (see Tables below). These limits should not be viewed as a recommendation on the number of embryos to transfer. These limits differ depending on the developmental stage of the embryos and the quality of the embryos and take into account the patient’s personal history.

| Limits on the number of embryos to transfer |
|------------------|------------------|------------------|------------------|
| Age < 35 | Age 35-37 | Age 38-40 | Age ≥ 41 |
| Blastocysts | | | |
| --favorable | 1 | 1 | ≤ 2 | ≤ 3 |
| --not favorable | ≤ 2 | ≤ 2 | ≤ 3 | ≤ 3 |

Other Favorable = Any ONE of these criteria: Fresh cycle: expectation of 1 or more high-quality embryos available for cryopreservation, or previous live birth after an IVF cycle. FET cycle: availability of vitrified day-5 or day-6 blastocysts, euploid embryos, 1st FET cycle, or previous live birth after an IVF cycle.

In some cases, there will be additional embryos remaining in the lab after the transfer is completed. Depending on their developmental normalcy, it may be possible to freeze them for later use. (See section 2.c. for an in-depth discussion of embryo cryopreservation).

**Hormonal support of the uterine lining**

- Successful attachment of embryo(s) to the uterine lining depends on adequate hormonal support.
- Progesterone, given by the intramuscular or vaginal route, is routinely given for this purpose.

Successful attachment of embryos to the uterine lining (endometrium) depends on adequate hormonal support of the lining. The critical hormones in this support are progesterone and
estradiol. Normally, the ovary makes sufficient amounts of both hormones. However, in IVF cycles, this support is not always adequate. Therefore, progesterone is routinely given, and in some cases, estradiol is also prescribed. Progesterone is given by the intramuscular or vaginal route. Estradiol is given by the oral, vaginal, trans-dermal or intramuscular route. The duration of this support is from 2 to 10 weeks.

**Additional Elements**

**Cryopreservation**

- Freezing of embryos can provide additional chances for pregnancy.
- Frozen embryos do not always survive the process of freezing and thawing.
- Ethical and legal dilemmas can arise when couples separate or divorce, especially for embryos; disposition agreements are essential.
- It is the responsibility of each couple with frozen eggs and/or embryos to remain in contact with the clinic on an annual basis.

Freezing (or “cryopreservation”) of embryos is a common procedure. Since multiple eggs (oocytes) are often produced during ovarian stimulation, on occasion there are more embryos available than are considered appropriate for transfer to the uterus. Such embryos can be frozen for future use. This strategy can save the expense and inconvenience of stimulation to obtain additional eggs in the future. Furthermore, the availability of cryopreservation permits patients to transfer fewer embryos during a fresh cycle, reducing the risk of high-order multiple gestations (triplets or greater). Other possible reasons for cryopreservation of embryos include freezing all embryos in the initial cycle to prevent severe ovarian hyperstimulation syndrome (OHSS), or if a couple were concerned that their future fertility potential might be reduced due to necessary medical treatment (e.g., cancer therapy or surgery). The pregnancy success rates for cryopreserved embryos transferred into the human uterus can vary from practice to practice. Overall pregnancy rates at the national level with frozen embryos are lower than with fresh embryos. This, at least in part, results from the routine selection of the best-looking embryos for fresh transfer, reserving the “second-best” for freezing. There is some evidence that pregnancy rates are similar when there is no such selection.

**Indications:**
- To reduce the risks of multiple gestation
- To preserve fertility potential in the face of certain necessary medical procedures
- To increase the chance of having one or more pregnancies from a single cycle of ovarian stimulation
- To minimize the medical risk and cost to the patient by decreasing the number of stimulated cycles and egg retrievals
- To temporarily delay pregnancy and decrease the risks of hyperstimulation (OHSS- see below) by freezing all embryos, when this risk is high

**Risks of cryopreservation:** There are several techniques for embryo cryopreservation, and research is ongoing. Traditional methods include “slow,” graduated freezing in a computerized setting, and “rapid” freezing methods, called “vitrification.” Current techniques deliver a high percentage of viable embryos thawed after cryopreservation, but there can be no certainty that embryos will thaw normally, nor be viable enough to divide and eventually implant in the uterus. Cryopreservation techniques could theoretically be injurious to the embryo. Extensive animal data (through several generations), and limited human data, do not indicate any likelihood that children born of embryos that have been cryopreserved and thawed will experience greater risk of abnormalities than those born of fresh embryos. However, until very large numbers of children have been born following freezing and thawing of embryos, it is not possible to be certain that the rate of abnormalities is no different from the normal rate.
If you choose to freeze embryos, you MUST complete and notarize the Disposition of Embryos statement before freezing. This statement outlines the choices you have with regard to the disposition of embryos in a variety of situations that may arise. You are free to submit a statement at a later time indicating different choices, provided you both agree in writing. It is also incumbent upon you to remain in touch with the clinic regarding your residence, and to pay for storage charges as they come due.

Risks to the Woman

Ovarian Hyperstimulation Syndrome

The intent of giving gonadotropins is to mature multiple follicles, but some women have an excessive response to the medications and are at risk for ovarian hyperstimulation syndrome (OHSS). This is the most serious side effect of ovarian stimulation. Its symptoms can include increased ovarian size, nausea and vomiting, accumulation of fluid in the abdomen, breathing difficulties, an increased concentration of red blood cells, kidney and liver problems, and in the most severe cases, blood clots, kidney failure, or death. The severe cases affect only a very small percentage of women who undergo in vitro fertilization—0.2 percent or less of all treatment cycles—and the very severe are an even smaller percentage. Only about 1.4 in 100,000 cycles has lead to kidney failure, for example. OHSS occurs at two stages: early, 1 to 5 days after egg retrieval (as a result of the hCG trigger); and late, 10 to 15 days after retrieval (as a result of the hCG if pregnancy occurs). The risk of severe complications is about 4 to 12 times higher if pregnancy occurs which is why sometimes no embryo transfer is performed to reduce the possibility of this occurring.

Cancer

Many have worried that the use of fertility drugs could lead to an increased risk of cancer—in particular, breast, ovarian, and uterine (including endometrial) cancers. One must be careful in interpreting epidemiological studies of women taking fertility drugs, because all of these cancers are more common in women with infertility, so merely comparing women taking fertility drugs with women in the general population inevitably shows an increased incidence of cancer. When the analysis takes into account the increased cancer risk due to infertility per se, the evidence does not support a relationship between fertility drugs and an increased prevalence of breast or ovarian cancer. A final answer may require decades of follow-up to resolve. Note that an increased chance for “borderline” ovarian tumors has been observed with IVF, even when compared to the subfertile population (see reference section for citation). More research is required to examine what the long-term impact fertility drugs may have on breast and ovarian cancer prevalence rates. For uterine cancer, the numbers are too small to achieve statistical significance, but it is at least possible that use of fertility drugs may indeed cause some increased risk of uterine cancer.

Risks of Pregnancy

Pregnancies that occur with IVF are associated with increased risks of certain conditions (see Table below from the Executive Summary of a National Institute of Child Health and Human Development Workshop held in September 2005, as reported in the journal Obstetrics & Gynecology, vol. 109, no. 4, pages 967-77, 2007). Some of these risks stem from the higher average age of women pregnant by IVF and the fact that the underlying cause of infertility may be the cause of the increased risk of pregnancy complications. This was demonstrated in an Australian study that reviewed adverse obstetric and perinatal outcomes in sub-fertile women conceiving without ART (see Table below). There may be additional risks related to the IVF procedure per se, but it is difficult to assign the relative contributions.

Potential Risks in Singleton IVF-conceived Pregnancies
### Maternal Risks

<table>
<thead>
<tr>
<th>Condition</th>
<th>Absolute Risk (%) in IVF-conceived Pregnancies</th>
<th>Relative Risk (vs. non IVF-conceived Pregnancies in a control population)</th>
<th>Relative Risk of Non-IVF Infertile Patients (vs. control population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-eclampsia</td>
<td>10.3%</td>
<td>1.6 (1.2-2.0)</td>
<td>1.29 (1.02-1.61)</td>
</tr>
<tr>
<td>Placenta previa</td>
<td>2.4%</td>
<td>2.9 (1.5-5.4)</td>
<td></td>
</tr>
<tr>
<td>Placental abruption</td>
<td>2.2%</td>
<td>2.4 (1.1-5.2)</td>
<td></td>
</tr>
<tr>
<td>Gestational diabetes</td>
<td>6.8%</td>
<td>2.0 (1.4-3.0)</td>
<td>1.25 (0.96-1.63)</td>
</tr>
<tr>
<td>Cesarean delivery *</td>
<td>26.7%</td>
<td>2.1 (1.7-2.6)</td>
<td>1.56 (1.37-1.77)</td>
</tr>
</tbody>
</table>

In this table, the Absolute risk is the percent of IVF Pregnancies in which the risk occurred. The Relative Risk is the risk in IVF versus the risk in non-IVF, non-infertile pregnancies; for example, a relative risk of 2.0 indicates that twice as many IVF pregnancies experience this risk as compared to non-IVF pregnancies. However, the third column indicates the increased risk of adverse outcome in infertile women conceiving without ART suggesting that being infertile increases the risk of adverse outcomes unrelated to ART/IVF. The numbers in parentheses (called the “Confidence Interval”) indicate the range in which the actual Relative Risk lies.

* Please note that most experts believe the rate of Cesarean delivery to be well above the 26.7% rate quoted here.

Multiple gestations, which account for 30% of IVF pregnancies, increase the risk of pregnancy complications. The most important maternal complications associated with multiple gestations are preterm labor and delivery, pre-eclampsia, and gestational diabetes. Placenta previa (placenta extends over the cervical opening), vasa previa (one or more of the blood vessels extends over the cervical opening), and placental abruption (premature separation of the placenta) are also more common in multiple gestations. Postpartum hemorrhage may complicate 12% of multifetal deliveries. Having triplets or more increases the risk of more significant complications including post-partum hemorrhage and transfusion. Other complications of multiple gestations include gall bladder problems, skin problems, excess weight gain, anemia, excessive nausea and vomiting, and exacerbation of pregnancy-associated gastrointestinal symptoms.

Although embryos are transferred directly into the uterus with IVF, ectopic (tubal, cervical and abdominal) pregnancies have occurred either alone or concurrently with a normal intra-uterine pregnancy. These abnormal pregnancies oftentimes require medical treatments with methotrexate (a weak chemotherapy drug) or surgery to treat the abnormal pregnancy.

### Risks to Offspring

- IVF babies seem to be at a slight increased risk for birth defects.
- The risk for a multiple pregnancy is significantly higher for patients undergoing IVF, even when only one embryo is transferred.
- Multiple pregnancies are the greatest risk for babies following IVF.
- Some risk may also stem from the underlying infertile state, or from the IVF techniques, or both.

### Overall Risks

Since the first birth of an IVF baby in 1978, more than 5 million children have been born worldwide following IVF treatments. Numerous studies have been conducted to assess the overall health of IVF children and the majority of studies on the safety of IVF have been reassuring. A major problem in interpreting the data arises from the fact that comparing a group of infertile couples to a group of normally fertile couples is not the proper comparison to make if one wants to assess the risk that IVF technology engenders. Infertile couples, by definition, do not have normal reproductive function and might be expected to have babies with more abnormalities than a group of normally fertile couples. This said, even if the studies suggesting an increased risk to babies born after IVF prove to be true, the absolute risk of any abnormal outcome appears to be small.
Singletons conceived with IVF tend to be born slightly earlier than naturally conceived babies (39.1 weeks as compared to 39.5 weeks). IVF twins are not born earlier or later than naturally conceived twins. The risk of a singleton IVF conceived baby being born with a birth weight under 5 pounds nine ounces (2500 grams) is 12.5% vs. 7% in naturally conceived singletons.

**Birth Defects**

The risk of birth defects in the normal population is 2-3%, and is slightly higher among infertile patients. Most of this risk is due to delayed conception and the underlying infertility issues. In a recent large study performed in Australia (see reference), the risk of birth defects was not increased among women who had routine IVF treatment, but was higher among those who employed ICSI as part of the treatment. No higher risk was seen in frozen embryo transfer and donor egg cycles.

**Imprinting Disorders.** These are rare disorders having to do with whether a maternal or paternal gene is inappropriately expressed. In two studies of children with the imprinting disorder called Beckwith-Weidemann Syndrome, more were born after IVF than expected. A large Danish study, however, found no increased risk of imprinting disorders in children conceived with the assistance of IVF. Since the incidence of this syndrome in the general population is 1/15,000, even if there is a 2 to 5-fold increase to 2-5/15,000, this absolute risk is very low.

**Childhood cancers.** Most studies have not reported an increased risk with the exception of retinoblastoma: In one study in the Netherlands, five cases were reported after IVF treatment which is 5 to 7 times more than expected. Further studies have not supported this finding.

**Infant development.** In general, studies of long-term developmental outcomes have been reassuring so far; most children are doing well. However, these studies are difficult to do and suffer from limitations. A more recent study with better methodology reports an increased risk of cerebral palsy (3.7 fold) and developmental delay (4 fold), but most of this stemmed from the prematurity and low birth weight that was a consequence of multiple pregnancy.

### Potential Risks in Singleton IVF Pregnancies

<table>
<thead>
<tr>
<th>Risk</th>
<th>Absolute Risk (%) in IVF Pregnancies</th>
<th>Relative Risk (vs. non-IVF Pregnancies)</th>
<th>Relative Risk for infertile women without ART</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preterm birth</td>
<td>11.5%</td>
<td>2.0 (1.7--2.2)</td>
<td>1.32 (1.05-1.67)</td>
</tr>
<tr>
<td>Low birth weight (&lt; 2500 g)</td>
<td>9.5%</td>
<td>1.8 (1.4--2.2)</td>
<td>1.44 (1.11-1.85)</td>
</tr>
<tr>
<td>Very low birth weight (&lt; 1500 g)</td>
<td>2.5%</td>
<td>2.7 (2.3--3.1)</td>
<td></td>
</tr>
<tr>
<td>Small for gestational age</td>
<td>14.6%</td>
<td>1.6 (1.3--2.0)</td>
<td>0.99</td>
</tr>
<tr>
<td>NICU (intensive care) admission</td>
<td>17.8%</td>
<td>1.6 (1.3--2.0)</td>
<td></td>
</tr>
<tr>
<td>Stillbirth</td>
<td>1.2%</td>
<td>2.6 (1.8--3.6)</td>
<td></td>
</tr>
<tr>
<td>Neonatal mortality</td>
<td>0.6%</td>
<td>2.0 (1.2--3.4)</td>
<td>2.19 (1.10-4.36)</td>
</tr>
<tr>
<td>Cerebral palsy</td>
<td>0.4%</td>
<td>2.8 (1.3--5.8)</td>
<td></td>
</tr>
<tr>
<td>Genetic risks</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-imprinting disorder</td>
<td>0.03%</td>
<td>17.8 (1.8--432.9)</td>
<td></td>
</tr>
<tr>
<td>-major birth defect</td>
<td>4.3%</td>
<td>1.5 (1.3--1.8)</td>
<td></td>
</tr>
<tr>
<td>-chromosomal abnormalities after ICSI</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-of a sex chromosome</td>
<td>0.6%</td>
<td>3.0</td>
<td></td>
</tr>
<tr>
<td>-of another chromosome</td>
<td>0.4%</td>
<td>5.7</td>
<td></td>
</tr>
</tbody>
</table>

In this table, the absolute risk is the percent of IVF pregnancies in which the risk occurred. The relative risk is the risk in IVF versus the risk in non-IVF pregnancies. For example, a relative risk of 2.0 indicates that twice as many IVF pregnancies experience this risk as compared to non-IVF pregnancies. The numbers in parentheses (called the “Confidence Interval”) indicate the range in which the actual relative risk lies.

### Risks of a Multiple Pregnancy
Currently, more than 30% of IVF pregnancies are twins or higher-order multiple gestations (triplets or greater), and about half of all IVF babies are a result of multiple gestations. Identical twinning occurs in 1.5% to 4.5% of IVF pregnancies, and may occur more frequently after blastocyst transfer.

Prematurity accounts for most of the excess perinatal morbidity and mortality associated with multiple gestations. IVF twins deliver on average three weeks earlier and weigh 1,000 gm less than IVF singletons. Triplet (and greater) pregnancies deliver before 32 weeks (7 months) in almost half of cases. Fetal growth problems and discordant growth among the fetuses also result in perinatal morbidity and mortality. Multifetal pregnancy reduction (where one or more fetuses are terminated) reduces, but does not eliminate, the risk of these complications.

Fetal death rates for singleton, twin, and triplet pregnancies are 4.3 per 1,000, 15.5 per 1,000, and 21 per 1,000, respectively. The death of one or more fetuses in a multiple gestation (vanishing twin) is more common in the first trimester and may be observed in up to 25% of pregnancies after IVF. Loss of a fetus in the first trimester is unlikely to adversely affect the surviving fetus.

Multiple fetuses that share the same placenta, as in most identical twins, have additional risks. Twin-twin transfusion syndrome, in which excess or insufficient amniotic fluid results from an imbalance of circulation between the fetuses, may occur in up to 20% of twins sharing a placenta. Twins sharing the same placenta have a higher frequency of birth defects compared to twins with two placentas. After the first trimester, death of one fetus in a twin pregnancy is more common with a shared placenta and may cause harm to the remaining fetus.

Long-term consequences of multiple gestations include the major complications of prematurity (cerebral palsy, retinopathy of prematurity, and chronic lung disease), as well as those of fetal growth restriction (polycythemia, hypoglycemia, necrotizing enterocolitis). It is unclear to what extent multiple gestations themselves affect neuro-behavioral development in the absence of these complications. At mid-childhood, prematurely born offspring from multiple gestations have lower IQ scores, and multiple birth children have an increase in behavioral problems compared with singletons. It is not clear to what extent these risks are affected by IVF per se.

**The Option of Multifetal Pregnancy Reduction:** The greater the number of fetuses within the uterus, the greater is the risk for adverse perinatal and maternal outcomes. Patients with more than twins are faced with the options of continuing the pregnancy with all risks previously described, terminating the entire pregnancy, or undergoing a procedure called multifetal pregnancy reduction. By reducing the number of fetuses, multifetal pregnancy reduction (MFPR) decreases risks associated with preterm delivery, but often creates important ethical dilemmas. Pregnancy loss is the main risk of MFPR. However, current data suggest that such complications have decreased as experience with the procedure has grown. The risk of loss of the entire pregnancy after MFPR is approximately 1%, although this risk increases when the number of fetuses prior to the procedure is greater than three.

**Ethical and Religious Considerations in Infertility Treatment**

Infertility treatment can raise concerns and questions of an ethical or religious nature for some patients. The technique of in vitro fertilization (IVF) involves the creation of human embryos outside the body, and can involve the production of excess embryos and/or “high-order” multiple pregnancy (triplets or more). Patients and their spouses or partners who so desire are encouraged to consult with trusted members of their religious or ethnic community for guidance on their infertility treatment.

**Psychosocial Effects of Infertility Treatment**
A diagnosis of infertility can be a devastating and life-altering event that impacts on many aspects of a patient’s life. Infertility and its treatment can affect a patient and her spouse or partner medically, financially, socially, emotionally and psychologically. Feelings of anxiety, depression, isolation, and helplessness are not uncommon among patients undergoing infertility treatment. Strained and stressful relations with spouses, partners and other loved ones are not uncommon as treatment gets underway and progresses.

Rearing of twins and high-order multiples may generate physical, emotional, and financial stresses; and the incidence of maternal depression and anxiety is increased in women raising multiples.

Patients may consider working with mental health professionals who are specially trained in the area of infertility care, as well as with their health care team, to minimize the emotional impact of infertility treatments. National support groups are also available, such as RESOLVE, (www.resolve.org, Tel. 1-888-623-0744) or The American Fertility Association (AFA), (www.theafa.org, Tel: 1-888-917-3777).

### Alternatives to IVF

There are alternatives to IVF treatment including gamete Intrafallopian transfer (GIFT), zygote intrafallopian transfer (ZIFT) or tubal embryo transfer (TET) where eggs and sperm, fertilized eggs or developing embryos, respectively, are placed into the fallopian tube(s). Using donor sperm, donor eggs, adoption, or not pursuing treatment are also options. Gametes (sperm and/or eggs), instead of embryos may be frozen for future attempts at pregnancy in an effort to avoid potential future legal or ethical issues relating to disposition of any cryopreserved embryos. Sperm freezing, but not egg freezing, has been an established procedure for many decades.

### Reporting Outcomes

The 1992 Fertility Clinic Success Rate and Certification Act requires the Centers for Disease Control and Prevention (CDC) to collect cycle-specific data as well as pregnancy outcome on all assisted reproductive technology cycles performed in the United States each year and requires them to report success rates using these data. Consequently, data from my/our IVF procedure will be provided to the CDC, and to the Society of Assisted Reproductive Technologies (SART) of the American Society for Reproductive Medicine (ASRM) (if my/our clinic is a member of this organization). The CDC may request additional information from the treatment center or contact me/us directly for additional follow-up. Additionally, my/our information may be used and disclosed in accordance with HIPAA guidelines in order to perform research, data aggregation and/or quality control. All information used for research will be de-identified prior to publication. De-identification is a process intended to prevent the data associated with my/our treatment being used to identify me/us as individuals.

### Additional Information

*General IVF overviews available on the internet*

- www.reproductivefacts.org
- www.sart.org/
- www.cdc.gov/art/
- www.resolve.org/site/PageServer
**Number of Embryos to Transfer**


**Culturing Embryos to the Blastocyst Stage**


**Ovarian Hyperstimulation**


**Risks of pregnancy**


**Risks to offspring**


We (I) acknowledge that we have read and understood the information provided above regarding the INVO process and its risk, and agree to go forward with this treatment as our signatures below testify.

\[ X \]
Patient Signature
Date

Patient Name
Date of Birth

Notary Public
Sworn and subscribed before me on this _____ day of _______, ________.

Notary Signature
Date

\[ NOTARY SEAL\]

\[ X\]
Spouse / Partner Signature
Date

Spouse / Partner Name
Date of Birth

Notary Public
Sworn and subscribed before me on this _____ day of _______, ________.

Notary Signature
Date

\[ NOTARY SEAL\]
**IVF Treatment Plan**

**Patient name:** _________________________ **Date:** ________________

**Spouse / partner name:** _____________________ **for IVF when?** ______________

**Provider of Sperm.**

We (I) plan to use sperm from:

- [ ] Spouse / partner
- [ ] Donor (specify name or number): ________________________________
- [ ] Other (specify arrangement): ________________________________

**Carrier of embryos.**

We (I) plan to transfer the embryos into:

- [ ] Me, the intended parent
- [ ] A Gestational Carrier
  ----*if known, her name: ________________________________

**Limit on Number Inseminated?**

Regarding the number of eggs to expose to sperm, we (I) choose:

- [ ] Inseminate ALL Mature Eggs
- [ ] Inseminate SOME Mature Eggs

  Number or fraction of eggs to be exposed to sperm: _______

**Plan for Eggs NOT Inseminated (if applicable).**

Regarding the eggs not exposed to sperm for fertilization we (I) choose:

- [ ] Freeze for my later use (requires Disposition Declaration)
- [ ] Donate to:
  - [ ] Research
  - [ ] Another person or couple
- [ ] Discard. This disposal will follow ASRM Ethical Guidelines. These extra eggs will no longer be available for attempting a pregnancy.
Plan for Embryos to Transfer.

Regarding the number of embryos to transfer, we (I) elect the following option:

- We (I) elect to transfer the number of embryos as outlined in the above table entitled "Limits on the number of embryos to transfer" (page 6).
- We (I) prefer to transfer fewer embryos. If a fewer number of embryo(s) will be transferred, please indicate that number in the space provided here ____________.
- We (I) prefer to transfer more than the limited number of embryos. If more than the limited number of embryos will be transferred, please indicate that number in the space provided here ____________. * We (I) understand this selection will require further consultation and approval from my (our) physician.

Physician approval to transfer an unfavorable number of embryos:

__________________________________________  __________________
Physician Signature  Date

Physician consultation notes:
__________________________________________
__________________________________________
__________________________________________

Initials: _____ / _____

Plan for Embryos NOT Transferred.

Regarding the disposition of embryos not transferred, we (I) elect the following option:

- Freeze Excess Embryos (requires Disposition Declaration)
- Donate Excess Embryos to:
  - Research
  - Another person or couple
- Discard Excess Embryos. This disposal will follow ASRM Ethical Guidelines. These extra embryos will no longer be available for attempting a pregnancy.

Initials: _____ / _____

Patient signature:  _____________________________________
Partner / spouse signature:  _____________________________________
Staff signature:  _____________________________________
Date:  __________________________